# Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone

> **NCT02015546** · PHASE3 · COMPLETED · sponsor: **Duke University** · enrollment: 70 (actual)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** Vilazodone

## Key facts

- **NCT ID:** NCT02015546
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02015546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02015546, "Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02015546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*